Adapting Biotech Leadership Across Development and Therapies
About this episode
This episode discusses the challenges and strategies of biotech leadership across different development stages with insights from Dr. Benit Maru.
Biotech leaders are asked to do a lot; move fast, manage limited resources, and guide teams through very different stages of development. In this episode of The Emerging Biotech Leader , host Kim Kushner talks with Dr. Benit Maru, Senior Vice President at SSI Strategy, about what it really looks like to lead in that environment. They cover: The contrasts between early and late development leadership, and why those transitions can feel like two different roles How scenario planning and structured conversations help teams prepare for uncertainty Why documents like the clinical development plan or target product profile should be seen as living tools, not paper exercises The similarities and differences in leading across modalities—devices, biologics, and advanced therapies like cell and gene The importance of team dynamics, culture, and knowing when to bring in outside expertise This episode is full of practical takeaways for biotech leaders who want to keep their strategies sound, their teams aligned, and their programs moving forward under pressure.
More episodes of The Emerging Biotech Leader
- Rethinking Trial Design for Rare Diseases
- Rare Disease Commercialization: Beyond Approval
- Clinical Operations as a Strategic Function
- How Clinical Operations Shapes Biotech Strategy
- 50 Episodes in: Lessons from The Emerging Biotech Leader
- Biotech Leadership: The CEO–CMO Dynamic
Explore listener stats, chart rankings, contacts and more on the The Emerging Biotech Leader podcast page.